Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Genetic rearrangements of the tyrosine receptor kinase ROS proto-oncogene 1 (ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC). We report the results of an updated integrated analysis of three phase I or II clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2) of the ROS1 tyrosine...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziadziuszko, Rafal, Krebs, Matthew G., De Braud, Filippo, Siena, Salvatore, Drilon, Alexander, Doebele, Robert C., Patel, Manish R., Cho, Byoung Chul, Liu, Stephen V., Ahn, Myung-Ju, Chiu, Chao-Hua, Farago, Anna F., Lin, Chia-Chi, Karapetis, Christos S., Li, Yu-Chung, Day, Bann-mo, Chen, David, Wilson, Timothy R., Barlesi, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078299/
https://www.ncbi.nlm.nih.gov/pubmed/33646820
http://dx.doi.org/10.1200/JCO.20.03025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078299/
https://www.ncbi.nlm.nih.gov/pubmed/33646820
http://dx.doi.org/10.1200/JCO.20.03025

Ejemplares similares